Stock Market & Financial Investment News

News Breaks January 18, 2013 06:25 EDT PFE Pfizer's Zoetis could be valued at up to $12.5B in IPO, Reuters reports Pfizer's (PFE) Zoetis unit could be valued at up to $12.5B in an IPO, Reuters reports. The animal health business is planning to sell 86.1M shares for $22-$25 each, raising about $2.2B at the top-end of the expected range; the IPO is expected to be priced on January 1. Reference Link News For PFE From The Last 14 Days Check below for free stories on PFE the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 16, 2013 08:55 EDT PFE BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information May 10, 2013 16:29 EDT PFE On The Fly: Closing Wrap Subscribe for More Information 12:31 EDT PFE On The Fly: Midday Wrap Subscribe for More Information 11:48 EDT PFE Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 09:21 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 08:08 EDT PFE Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence. 07:46 EDT PFE DURECT says additional clinical studies needed for Remoxy DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39. May 9, 2013 10:17 EDT PFE Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information May 8, 2013 10:33 EDT PFE Bristol-Myers, Pfizer announced results from ARISTOTLE trial subanalysis Bristol-Myers (BMY) and Pfizer (PFE) announced yesterday that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from the subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. This story corrects a headline from yesterday. May 7, 2013 12:32 EDT PFE High option volume stocks: ALDW BC NMM PFE AEP 08:09 EDT PFE Accelrys, Pfizer extend agremeent for global deployment of Lifecycle software Subscribe for More Information May 6, 2013 17:03 EDT PFE Bristol-Myers, Pfizer announce publication of ARISTOTLE trial Bristol-Myers Squibb (BMY) and Pfizer (PFE) announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. Based on the results of the subanalysis, the benefits of Eliquis compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers' and patients' quality of INR control. 08:02 EDT PFE Pfizer launches Viagra home delivery, powered by CVS/pharmacy To meet the needs of consumers who are increasingly going online to purchase prescription medications, Pfizer (PFE) launched Viagra home delivery, a new prescription-fulfillment website for Viagra tablets, Pfizer’s most counterfeited medicine. The site, which is powered by CVS/pharmacy (CVS) and accessible through Viagra.com, offers men with erectile dysfunction an opportunity to purchase Viagra online with a valid prescription from a trusted source. 07:51 EDT PFE Pfizer to sell Viagra directly to patients on its website, Fox News reports In a move that changes the drug industry's distribution model, Pfizer told The Associated Press that it will begin selling Viagra directly to patients on its website, reports Fox News. Men still will need a prescription to buy it, and Pfizer is offering three free pills with the first order and 30% off the second one. Reference Link 07:34 EDT PFE Conference Forum to host a summit Subscribe for More Information 07:24 EDT PFE Drug companies attempt to make painkillers that can't be abused, WSJ reports Subscribe for More Information 07:18 EDT PFE American Congress of Obstetrics and Gynecology to hold annual meeting Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.